{
  "first_published_at": "2013-06-24", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON286975", 
  "title": "Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety", 
  "tags": "{\"parsed_therapeutic\": [\"pain-management-palliation\", \"rheumatology\", \"dentistry\"], \"Audience:\": [\"Secondary care\", \"Primary care\", \"Dentists\"], \"Therapeutic area:\": [\"Pain management and palliation\", \"Rheumatology\"]}", 
  "_document_number": 70, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "pain-management-palliation", 
    "rheumatology", 
    "dentistry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Available data indicate that the cardiovascular risk with diclofenac is similar to that of the selective COX-2 inhibitors. Consistent with COX-2 inhibitors, diclofenac is now contraindicated in those with: ischaemic heart disease; peripheral arterial disease; cerebrovascular disease; or established congestive heart failure (New York Heart Association [NYHA] classification II&#8211;IV). The new treatment advice applies to systemic formulations (ie, tablets, capsules, suppositories, and injection available both on prescription and via a pharmacy, P); it does not apply to topical (ie, gel or cream) formulations of diclofenac<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>An increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs)&#8212;such as diclofenac&#8212;is well recognised, particularly with long-term use of high doses and in patients who are already at high risk. Warnings for healthcare professionals and patients have been included in the product information and in the British National Formulary for some years.</p>\n\n<p>The European Medicines Agency&#8217;s Pharmacovigilance Risk Assessment Committee has recently recommended updates to the treatment advice for diclofenac in light of the findings of a Europe-wide review of the cardiovascular safety of NSAIDs. The review found further evidence that the arterial thrombotic risk with diclofenac is similar to that for the selective COX-2 inhibitors.</p>\n\n<p>The new treatment advice applies to systemic formulations (ie, tablets, capsules, suppositories, and injection available both on prescription and via a pharmacy, P); it does not apply to topical (ie, gel or cream) formulations of diclofenac.</p>\n\n<p>A recently published meta-analysis <cite>Coxib and traditional NSAID Trialists&#8217; (CNT) Collaboration. <a href=\"http://dx.doi.org/10.1016/S0140-6736(13)60900-9\" target=\"_blank\">Lancet published online May 20, 2013</a></cite> of clinical trial data provides further evidence that the arterial thrombotic risk with diclofenac is similar to that of COX-2 inhibitors. This analysis found that of 1000 patients allocated to diclofenac for a year, three more had major vascular events, compared with placebo.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p><em>New advice for diclofenac:</em></p>\n\n<ul>\n<li>Diclofenac is now contraindicated in patients with established: \n\n<ul>\n<li>ischaemic heart disease</li>\n\n<li>peripheral arterial disease</li>\n\n<li>cerebrovascular disease</li>\n\n<li>congestive heart failure (New York Heart Association [NYHA] classification II&#8211;IV)</li>\n</ul>\n\n<p>Patients with these conditions should be switched to an alternative treatment at their next routine appointment</p>\n</li>\n\n<li>Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking)</li>\n</ul>\n\n<p><em>Reminder of existing advice for all NSAIDs:</em></p>\n\n<ul>\n<li>The <a href=\"http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation\" target=\"_blank\">decision to prescribe</a> an NSAID should be based on an assessment of a patient&#8217;s individual risk factors, including any history of cardiovascular and gastrointestinal illness</li>\n\n<li>Naproxen and low-dose ibuprofen are considered to have the most favourable thrombotic cardiovascular safety profiles of all non-selective NSAIDs</li>\n\n<li>The lowest effective dose should be used for the shortest duration necessary to control symptoms. A patient&#8217;s need for symptomatic relief and response to treatment should be re-evaluated periodically</li>\n</ul>\n\n<p><strong>Additional advice for pharmacists:</strong></p>\n\n<p><em>Non-prescription availablility of diclofenac:</em></p>\n\n<p>Diclofenac is available to buy in a pharmacy without a prescription at low doses (up to 75 mg/day) for short-term use (3 days). Pharmacists are asked to take the following steps when supplying diclofenac without prescription:</p>\n\n<ul>\n<li>Ask questions to exclude supply for use by people with established cardiovascular disease and people with significant risk factors for cardiovascular events</li>\n\n<li>Advise patients to take diclofenac only for 3 days before seeking medical advice</li>\n\n<li>Advise patients to take only one NSAID at a time</li>\n</ul>\n</div>\n\n<p>This information will be circulated via the<a href=\"https://www.cas.dh.gov.uk\" target=\"_blank\"> NHS Central Alerting System</a> in early July.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><em>New advice:</em></p>\n\n<p>- Message sent via the <a href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101971\" target=\"_blank\">NHS Central Alerting System</a>, including <a href='/Safetyinformation/DrugSafetyUpdate/CON295485' target=\"_blank\">material to pass on to patients</a>.</p>\n\n<p>- European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001816.jsp&#38;mid=WC0b01ac058004d5c1\" target=\"_blank\">statement</a></p>\n\n<p><em>Reminder of existing advice:</em></p>\n\n<p>- European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000316.jsp&#38;mid=WC0b01ac0580225ca9#section5\" target=\"_blank\">public assessment report, October 2012</a></p>\n\n<p>- Previous NSAID advice from Drug Safety Update (<a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199570\" target=\"_blank\">October 2012</a>, <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130\" target=\"_blank\">February 2009</a>, <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694\">December 2007</a>)</p>\n\n<p><em>General NSAID advice:</em></p>\n\n<p>- <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm\" target=\"_blank\">MHRA website information on NSAIDs</a></p>\n\n<p>- <a href=\"http://www.bnf.org/bnf/search.htm?q=diclofenac\" target=\"_blank\">British National Formulary</a></p>\n\n<p>- <a href=\"http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation\" target=\"_blank\">Clinical Knowledge Summaries on NSAID prescribing</a></p>\n\n<p><em>Article citation: Drug Safety Update vol 6, issue 11 June 2013: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>An increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs)&#8212;such as diclofenac&#8212;is well recognised, particularly with long-term use of high doses and in patients who are already at high risk. Warnings for healthcare professionals and patients have been included in the product information and in the British National Formulary for some years.</p>\n\n<p>The European Medicines Agency&#8217;s Pharmacovigilance Risk Assessment Committee has recently recommended updates to the treatment advice for diclofenac in light of the findings of a Europe-wide review of the cardiovascular safety of NSAIDs. The review found further evidence that the arterial thrombotic risk with diclofenac is similar to that for the selective COX-2 inhibitors.</p>\n\n<p>The new treatment advice applies to systemic formulations (ie, tablets, capsules, suppositories, and injection available both on prescription and via a pharmacy, P); it does not apply to topical (ie, gel or cream) formulations of diclofenac.</p>\n\n<p>A recently published meta-analysis <cite>Coxib and traditional NSAID Trialists&#8217; (CNT) Collaboration. <a href=\"http://dx.doi.org/10.1016/S0140-6736(13)60900-9\" target=\"_blank\">Lancet published online May 20, 2013</a></cite> of clinical trial data provides further evidence that the arterial thrombotic risk with diclofenac is similar to that of COX-2 inhibitors. This analysis found that of 1000 patients allocated to diclofenac for a year, three more had major vascular events, compared with placebo.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<p><em>New advice for diclofenac:</em></p>\n\n<ul>\n<li>Diclofenac is now contraindicated in patients with established: \n\n<ul>\n<li>ischaemic heart disease</li>\n\n<li>peripheral arterial disease</li>\n\n<li>cerebrovascular disease</li>\n\n<li>congestive heart failure (New York Heart Association [NYHA] classification II&#8211;IV)</li>\n</ul>\n\n<p>Patients with these conditions should be switched to an alternative treatment at their next routine appointment</p>\n</li>\n\n<li>Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking)</li>\n</ul>\n\n<p><em>Reminder of existing advice for all NSAIDs:</em></p>\n\n<ul>\n<li>The <a href=\"http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation\" target=\"_blank\">decision to prescribe</a> an NSAID should be based on an assessment of a patient&#8217;s individual risk factors, including any history of cardiovascular and gastrointestinal illness</li>\n\n<li>Naproxen and low-dose ibuprofen are considered to have the most favourable thrombotic cardiovascular safety profiles of all non-selective NSAIDs</li>\n\n<li>The lowest effective dose should be used for the shortest duration necessary to control symptoms. A patient&#8217;s need for symptomatic relief and response to treatment should be re-evaluated periodically</li>\n</ul>\n\n<p><strong>Additional advice for pharmacists:</strong></p>\n\n<p><em>Non-prescription availablility of diclofenac:</em></p>\n\n<p>Diclofenac is available to buy in a pharmacy without a prescription at low doses (up to 75 mg/day) for short-term use (3 days). Pharmacists are asked to take the following steps when supplying diclofenac without prescription:</p>\n\n<ul>\n<li>Ask questions to exclude supply for use by people with established cardiovascular disease and people with significant risk factors for cardiovascular events</li>\n\n<li>Advise patients to take diclofenac only for 3 days before seeking medical advice</li>\n\n<li>Advise patients to take only one NSAID at a time</li>\n</ul>\n</div>\n\n<p>This information will be circulated via the<a href=\"https://www.cas.dh.gov.uk\" target=\"_blank\">NHS Central Alerting System</a> in early July.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><em>New advice:</em></p>\n\n<p>- Message sent via the <a href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101971\" target=\"_blank\">NHS Central Alerting System</a>, including <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON295485\" target=\"_blank\">material to pass on to patients</a>.</p>\n\n<p>- European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001816.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">statement</a></p>\n\n<p><em>Reminder of existing advice:</em></p>\n\n<p>- European Medicines Agency <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000316.jsp&amp;mid=WC0b01ac0580225ca9#section5\" target=\"_blank\">public assessment report, October 2012</a></p>\n\n<p>- Previous NSAID advice from Drug Safety Update (<a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199570\" target=\"_blank\">October 2012</a>, <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130\" target=\"_blank\">February 2009</a>, <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694\">December 2007</a>)</p>\n\n<p><em>General NSAID advice:</em></p>\n\n<p>- <a href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm\" target=\"_blank\">MHRA website information on NSAIDs</a></p>\n\n<p>- <a href=\"http://www.bnf.org/bnf/search.htm?q=diclofenac\" target=\"_blank\">British National Formulary</a></p>\n\n<p>- <a href=\"http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation\" target=\"_blank\">Clinical Knowledge Summaries on NSAID prescribing</a></p>\n\n<p><em>Article citation: Drug Safety Update vol 6, issue 11 June 2013: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-06-01", 
  "date_last_modified": "2013-07-04", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "material to pass on to patients", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON295485", 
      "filename": "downloads/64045444f4a9b06231cdc1fc95d67c0c6e6d97d4/con295485.pdf", 
      "original_filename": "con295485.pdf"
    }
  ], 
  "_item_id": 70, 
  "summary": "Available data indicate that the cardiovascular risk with diclofenac is similar to that of the selective COX-2 inhibitors. Consistent with COX-2 inhibitors, diclofenac is now contraindicated in those with: ischaemic heart disease; peripheral arterial disease; cerebrovascular disease; or established congestive heart failure (New York Heart Association [NYHA] classification II–IV). The new treatment advice applies to systemic formulations (ie, tablets, capsules, suppositories, and injection available both on prescription and via a pharmacy, P); it does not apply to topical (ie, gel or cream) formulations of diclofenac", 
  "body": "Article date: June 2013\n\nAn increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs)—such as diclofenac—is well recognised, particularly with long-term use of high doses and in patients who are already at high risk. Warnings for healthcare professionals and patients have been included in the product information and in the British National Formulary for some years.\n\nThe European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has recently recommended updates to the treatment advice for diclofenac in light of the findings of a Europe-wide review of the cardiovascular safety of NSAIDs. The review found further evidence that the arterial thrombotic risk with diclofenac is similar to that for the selective COX-2 inhibitors.\n\nThe new treatment advice applies to systemic formulations (ie, tablets, capsules, suppositories, and injection available both on prescription and via a pharmacy, P); it does not apply to topical (ie, gel or cream) formulations of diclofenac.\n\nA recently published meta-analysis [^1] of clinical trial data provides further evidence that the arterial thrombotic risk with diclofenac is similar to that of COX-2 inhibitors. This analysis found that of 1000 patients allocated to diclofenac for a year, three more had major vascular events, compared with placebo. \n\nAdvice for healthcare professionals:\n\nNew advice for diclofenac:  \n  \n  * Diclofenac is now contraindicated in patients with established:   \n    * ischaemic heart disease  \n    * peripheral arterial disease  \n    * cerebrovascular disease  \n    * congestive heart failure (New York Heart Association [NYHA] classification II–IV)  \n  \nPatients with these conditions should be switched to an alternative treatment at their next routine appointment  \n  \n  * Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking)  \n  \nReminder of existing advice for all NSAIDs:  \n  \n  * The [decision to prescribe](http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation) an NSAID should be based on an assessment of a patient’s individual risk factors, including any history of cardiovascular and gastrointestinal illness  \n  * Naproxen and low-dose ibuprofen are considered to have the most favourable thrombotic cardiovascular safety profiles of all non-selective NSAIDs  \n  * The lowest effective dose should be used for the shortest duration necessary to control symptoms. A patient’s need for symptomatic relief and response to treatment should be re-evaluated periodically  \n  \nAdditional advice for pharmacists:\n\nNon-prescription availablility of diclofenac:\n\nDiclofenac is available to buy in a pharmacy without a prescription at low doses (up to 75 mg/day) for short-term use (3 days). Pharmacists are asked to take the following steps when supplying diclofenac without prescription:  \n  \n  * Ask questions to exclude supply for use by people with established cardiovascular disease and people with significant risk factors for cardiovascular events  \n  * Advise patients to take diclofenac only for 3 days before seeking medical advice  \n  * Advise patients to take only one NSAID at a time  \n  \nThis information will be circulated via the[NHS Central Alerting System](https://www.cas.dh.gov.uk) in early July.\n\nFurther information:\n\nNew advice:\n\n\\- Message sent via the [NHS Central Alerting System](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101971), including [ASSET_TAG](#ASSET0).\n\n\\- European Medicines Agency [statement](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001816.jsp&mid=WC0b01ac058004d5c1)\n\nReminder of existing advice:\n\n\\- European Medicines Agency [public assessment report, October 2012](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000316.jsp&mid=WC0b01ac0580225ca9#section5)\n\n\\- Previous NSAID advice from Drug Safety Update ([October 2012](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199570), [February 2009](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130), [December 2007](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694))\n\nGeneral NSAID advice:\n\n\\- [MHRA website information on NSAIDs](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm)\n\n\\- [British National Formulary](http://www.bnf.org/bnf/search.htm?q=diclofenac)\n\n\\- [Clinical Knowledge Summaries on NSAID prescribing](http://cks.nice.org.uk/nsaids-prescribing-issues#!scenariorecommendation)\n\nArticle citation: Drug Safety Update vol 6, issue 11 June 2013: A2.\n\n[^1]: Coxib and traditional NSAID Trialists’ (CNT) Collaboration. [Lancet published online May 20, 2013](http://dx.doi.org/10.1016/S0140-6736\\(13\\)60900-9)\n"
}